PLT 012
Alternative Names: PLT-012Latest Information Update: 04 Jul 2024
At a glance
- Originator Pilatus Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver cancer
- Research Inflammation
Most Recent Events
- 05 Apr 2024 Early research in Inflammation in Switzerland (Parenteral), prior to April 2024
- 05 Apr 2024 Preclinical trials in Liver cancer in Switzerland (Parenteral), prior to April 2024
- 05 Apr 2024 Pharmacodynamics and adverse event data from a preclinical trial in Liver cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)